Rydapt (midostaurin) FDA Approval History | 合法藥品大搜索

2017年4月28日 — FDA also approved midostaurin for the treatment of adults with aggressive systemic mastocytosis (SM), SM with associated hematological ... Read More

2017年4月28日 — The U.S. Food and Drug Administration today approved Rydapt (midostaurin) for the treatment of adult patients with newly diagnosed acute ... Read More

Newly diagnosed acute myeloid leukemia (AML) that is FLT3 mutation- positive as detected by an FDA-approved test, in combination with standard cytarabine and ... Read More

Information on FDA-approved tests for the detection of FLT3 mutation in AML is ... RYDAPT is contraindicated in patients with hypersensitivity to midostaurin or to ... Read More

This draft guidance, when finalized, will represent the current thinking of the Food and Drug. Administration (FDA, or the Agency) on this topic. It does not ... Read More

Date created: January 5, 2017. Back to Top Drugs@FDA. Vision impaired people having problems accessing certain pages of a PDF file may call (301) ... Read More

Newly diagnosed acute myeloid leukemia (AML) that is FLT3 mutation- positive as detected by an FDA-approved test, in combination with standard cytarabine and ... Read More

FDA approval history for Rydapt (midostaurin) used to treat Acute Myeloid Leukemia. Supplied by Novartis. Read More

由 YL Kasamon 著作 · 2018 · 被引用 21 次 — Midostaurin is the only U.S. Food and Drug Administration‐approved therapy for patients with systemic mastocytosis with associated hematological neoplasm and​ ... Read More

On April 28, 2017, the United States Food and Drug Administration (FDA) approved RYDAPT (midostaurin) for the treatment of adult patients with: Newly ... Read More